Zobrazeno 1 - 5
of 5
pro vyhledávání: '"O Pereira-Blanco"'
Autor:
M Pérez-Moreno, A Pinilla-Rello, I Larrodé-Leciñena, A Magallón-Martínez, L Cazorla-Poderoso, R Huarte-Lacunza, R M Martínez-Álvarez, A I López-Calleja, O Pereira-Blanco
Publikováno v:
Revista Española de Quimioterapia
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
RESUMEN Introducción Se necesitan datos comparativos en “vida real” sobre efectividad y seguridad de ceftolozano/tazobactam (C/T) frente otros regímenes (aminoglucósidos/colistina/combinación) en el tratamiento de Pseudomonas aeruginosa (PA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91fb2e9d4547a10b3eacd922d4c26994
https://pubmed.ncbi.nlm.nih.gov/34154319
https://pubmed.ncbi.nlm.nih.gov/34154319
Autor:
O Pereira Blanco, A Magallon Martinez, A Escolano Pueyo, A Casajús Navasal, R Abaz Sazatornil, MJ Agustín Ferrández, A Pinilla Rello, L Cazorla Poderoso, MA Perez Moreno
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The guidelines recommend anti-PD-1/PD-L1 immunotherapy as secondline treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), regardless of PD-L1 expression. Aim and objectives To evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eeb0dbdb3ab55000945828745f7d33d4
https://doi.org/10.1136/ejhpharm-2020-eahpconf.189
https://doi.org/10.1136/ejhpharm-2020-eahpconf.189
Autor:
O Pereira Blanco, Abad Sazatornil, V Gimeno Ballester, A Gasso, I Larrode Leciñena, P Olier Martinez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background The indication of palivizumab is the prevention of serious lower respiratory tract disease requiring hospitalisation caused by the respiratory syncytial virus (RSV) in children at high risk for RSV disease, but medication assessment in dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::499e740da53183d045fc8777073698b9
https://doi.org/10.1136/ejhpharm-2019-eahpconf.248
https://doi.org/10.1136/ejhpharm-2019-eahpconf.248
5PSQ-057 Olaparib and niraparib safety profile in the clinical practice of a tertiary-level hospital
Autor:
O Pereira Blanco, A Herrero Ibañez, H Navarro Aznarez, B Abad Bañuelos, A Casajús Navasal, Abad Sazatornil, A Magallon Martinez, A Pinilla Rello
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Olaparib and Niraparib are oral antineoplastics used for the maintenance treatment of high-grade ovarian cancer, relapsed, complete or partial response to platinum-based chemotherapy. Olaparib is indicated for patients with BRCA +mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43bf1d476c7db576257bae39f34ef375
https://doi.org/10.1136/ejhpharm-2019-eahpconf.490
https://doi.org/10.1136/ejhpharm-2019-eahpconf.490
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.